Learn About Litmys
Litmys' RAMPx™ Model
(Realistic Assessment of Market Potential)
"Demonstrating the value of new therapies requires strategic insight into clinical impact, adoption, and economics. Litmys' RAMPx™ model delivers this focus, aligning innovation with stakeholder priorities."
– Chief Medical and Scientific Officer, Global CRO
The Challenge of Commercial Success
Regulatory approval of life sciences products means little if payers, physicians, and patients don't adopt and use them. Approval doesn't guarantee commercial success.
Litmys' proprietary RAMPx™ model tests new product differentiation against real-world adoption drivers. It's a quantitative, 360° framework that consists of 12 factors that measure how compelling a product's value proposition is versus the standard of care.
RAMPx™ helps life sciences companies focus on what to fix, prove, or communicate in product development and commercialization.
Who RAMPx™ Supports
  • Pharmaceutical, biotech, and medical device companies developing or launching new products
  • Investors and boards needing objective, evidence-based commercial viability assessments
New Product Development is Challenging
Payer Pressure
Payers demand real world evidence before reimbursement
Physician Employment
77.6% of U.S. physicians are now employees under pressure to maximize patient volume
Limited Access
Half of physicians won't see pharmaceutical sales reps
Risk Aversion
One-third of U.S. physicians have been sued for malpractice, driving risk aversion to new products
What RAMPx™ Does
RAMPx™ looks beyond product advantages and goes deeper into the effort actually required to adopt the product by patients, caregivers and healthcare professionals.
Quantifies adoption potential
Quantifies adoption potential across 12 validated real-world drivers
Identifies gaps
Identifies where differentiation and adoption gaps exist, and what to course-correct before a Phase 3 clinical trial
Aligns clinical design
Aligns clinical design with real-world adoption readiness
Provides scoring
Provides a numeric "Adoption Readiness Score" to guide decision-making
Grounds assumptions
Grounds future revenue assumptions with real-world adoption barriers
Prioritizes resources
Prioritizes resources by allowing companies to focus on products and indications with the highest probability of success
The RAMPx™ Process
Litmys begins with what customers demand and works back.
Why RAMPx™ Matters
Differentiated
The only model that incorporates all the dimensions that really drive product adoption
Tested
RAMPx™ has accurately predicted future uptake for new products
Proven Approach
Uses a methodology similar to Nielsen's BASES for assessing new consumer products
Prescient
Able to project product success/failure/need for modification before heavy investments are made.
The RAMPx™ Model's
Comparative Product Performance Analysis
Analysis includes
  • Stakeholder-specific TPP ratings vs. Standard of Care
  • A comparative rating framework
  • Relative factor importance
  • Strength of value proposition scoring
  • Better alignment between clinical outcomes and commercial needs
Ready to Transform Your Product Development?
Discover how Litmys' RAMPx™ model can help you make accurate product development and portfolio decisions, build defensible forecasts, and succeed in a crowded, competitive market.
Contact Harris Kaplan, Managing Partner